Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: Efficacy and safety

Transplantation

Volumn 84, Issue 1, 2007, Pages 75-82

  Kyllönen, Lauri E ^a   Eklund, Björn H ^a   Pesonen, Eero J ^a   Salmela, Kaija T ^a  

^a Surgical Hospital   (Finland)

Author keywords

Basiliximab; Delayed graft function; High dose bolus antithymocyte globulin; Kidney transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CEFUROXIME; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTAMIDINE; STEROID; SULFATRIMETHOPRIM; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BILIARY TRACT DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GRAFT SURVIVAL; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SEPTICEMIA; SINGLE DRUG DOSE; URETER OBSTRUCTION; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DELAYED GRAFT FUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447639265     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000268084.64888.f3     Document Type: Article

References (23)

1. Kyllönen LEJ, Salmela KT, Eklund BH, et al. Long-term results of 1047 cadaveric kidney transplantations with special emphasis on initial graft function and rejection. Transpl Int 2000; 13: 122.
2. Kyllönen L, Salmela K. Transplantation of both kidneys from 408 donors; Comparison of results. Transpl Int 2000; 13 Suppl 1: S95.
3. Salmela K, Kyllönen L. Two decades of experience with cyclosporine in renal transplantation in Helsinki. Transplant Proc 2004; 36 Suppl: 94S.
4. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222.
5. Kaden J, May G, Mueller P, et al. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc 1995; 27: 1060.
6. Kaden J, Strobelt V, May G. Short and long-term results after pretransplant high-dose single ATG-Fresenius bolus in cadaveric kidney transplantation. Transplant Proc 1998; 30: 4011.
7. Schoulz T, Konzack J, Buesing M. Mycophenolate mofetil/prednisolone/ single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: First results of an ongoing prospective randomised trial. Transplant Proc 1999; 31: 591.
8. Sollinger H, Kaplan B, Pescowitz MD, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915.
9. Ponticelli C, Cambi V, Shapira Z, et al. A multicenter double-blind placebo controlled study of basiliximab (Simulect) in combination with triple therapy including azathioprine for the prevention of acute rejection episodes in renal allograft patients. Transplantation 1999; 67: S151.
10. Mulloy LL, Wright F, Hall ML, Moore M. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant Proc 1999; 31: 1210.
11. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701.
12. Turunen AJ, Lindgren L, Salmela KT, et al. Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation. Transplantation 2004; 77: 1821.
13. Turunen AJ, Fernandez JA, Lindgren L, et al. Activated protein C reduces graft neutrophil activation in clinical renal transplantation. Am J Transplant 2005; 5: 2204.
14. Matinlauri IH, Kyllönen LEJ, Eklund BH, et al. Weak humoral post-transplant alloresponse after a well-matched cadaveric kidney transplantation. Transplantation 2004; 78: 198.
15. Matinlauri IH, Kyllönen LEJ, Salmela KT, et al. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation 2005; 80: 1809.
16. Racusen L, Solez K, Colvin RB, et al. The Banff 97 working classification of kidney allograft pathology. Kidney Int 1999; 55: 713.
17. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. Transplantation 1988; 46: 223.
18. Esposito L, Kamar N, Tkaczuk J, et al. Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal transplant patients. Transplant Proc 2005; 37: 785.
19. Weimer R, Staak A, Suesal C, et al. ATG induction therapy: Long-term effects on Th1 but not Th2 responses. Transpl Int 2005; 18: 226.
20. Brennan D, Daller J, Lake K, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
21. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
22. Kaden J. Optimal management of induction therapy with ATG in kidney allograft recipients. Int J Immunotherapy 1999; 15: 115.
23. Schulz T, Papapostolou G, Schenker P, Kapischke M. Single-shot anti-thymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin. Transplant Proc 2005; 37: 1301.